Serotonergic psychedelics are re-emerging as therapeutic candidates across psychiatry, particularly for treatment-resistant depression. Their rapid and sustained antidepressant effects, alongside evidence for neuroplastic, dopaminergic, and glutamatergic modulation, have prompted interest in whether they could address depressive and negative symptoms in schizophrenia spectrum disorders (SSDs)....
As humanity has been utilizing psychedelic substances for millennia, much knowledge has already been accumulated about the exploratory potential and therapeutic power of the psychedelic-induced nonordinary states of consciousness (NSC). However, we still have only a limited understanding of the process that unfolds in mind and the brain. Only recently have systematic investigations become...